Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation
NCT07924943, Not applicable, Recruiting, AIO-Studien-gGmbH
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation | ClinicalTrials.gov |
| NCT number | NCT07924943 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 44 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | AIO-Studien-gGmbH | ClinicalTrials.gov |
| Conditions | HCC - Hepatocellular Carcinoma | ClinicalTrials.gov |
| Interventions | Stereotactic body radiation therapy (SBRT) in addition to TACE prior to liver transplantation, The patients will receive two procedures of TACE prior to liver transplantation | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Primary Endpoint: histopathological response (presence of vital tumor tissue) in explant histopathology after liver transplantation. | After liver transplantation (at least 24 months after randomization) | The percentage of vital tumor tissue is defined as the maximum percentage of vital tumor tissue per surface area per patient. | ClinicalTrials.gov |
| Secondary | Overall survival (OS) | 24 months after randomization | Overall survival (OS) is defined as time from randomization to death from any cause. Overall survival-rate at 24 months is defined as the (estimated) proportion of patients who are still alive 24 months after randomization. | ClinicalTrials.gov |
| Secondary | Objective response rate (ORR) | up to 24 months after randomization | The objective response rate (ORR) is defined as the proportion of all randomized patients in whom a CR or PR was observed | ClinicalTrials.gov |
| Secondary | Complete response rate (CRR) | up to 24 months after randomization | The complete response rate (CRR) is defined as the proportion of all randomized patients in whom a CR was observed | ClinicalTrials.gov |
| Secondary | Progression-free survival (PFS) | up to 24 months after randomization | Progression-free survival (PFS) is defined as time from randomization to objective tumor progression or death from any cause | ClinicalTrials.gov |
| Secondary | Recurrence Rate | up to 24 months after transplantation | Recurrence Rate is defined as the percentage of patients in whom cancer recurs after transplantation within 24 months. The recurrence is determined by regular standard of care follow-up examinations, which include imaging procedures (CT, MRI, ultrasound) and blood tests (e.g. alpha-fetoprotein). A division is made between local recurrence in the transplanted liver and distant metastases. | ClinicalTrials.gov |
| Secondary | Recurrence free survival (RFS) | up to 24 months after transplantation | Recurrence free survival (RFS) is defined as time from transplantation to tumor recurrence or death from HCC. Death from any other cause will be used as a censoring event. | ClinicalTrials.gov |
| Secondary | Quality of Life Assessments | up to 24 months after randomization | Quality of Life evaluated with EQ-5D-5L | ClinicalTrials.gov |
| Secondary | Safety reporting - treatment-emergent adverse events | Up to 24 months after informed consent | Type, incidence, causal relationship, and severity of treatment-emergent adverse events | ClinicalTrials.gov |
| Secondary | Safety reporting - albumin-bilirubin score (ALBI Score) | Up to 24 months after informed consent | Analysis of the effect on albumin-bilirubin score (ALBI Score) | ClinicalTrials.gov |
| Secondary | Safety reporting - Child Pugh Score | Up to 24 months after informed consent | Analysis of the effect on Child Pugh Score | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)